The purpose of this study is to test the effectiveness Secnidazole to treat recurrent BV. Secnidazole is approved for one-time use in acute BV. In this study, the drug will be used for recurrent BV, and given weekly for 18 weeks.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Subjects With at Least One Episode of Bacterial Vaginosis
Timeframe: 30 weeks
Probability of Failure at 210 Days
Timeframe: 210 days (30 weeks)
The Number of Subjects That Failed Treatment in the Supressive Phase
Timeframe: 30 weeks